Please use this identifier to cite or link to this item:
|Title:||Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review|
|Source:||Rogers, S.L., McIntosh, R.L., Lim, L., Cheung, N., Wang, J.J., Wong, T.Y., Mitchell, P., Kowalski, J.W., Nguyen, H.P. (2010). Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review. Ophthalmology 117 (6). ScholarBank@NUS Repository. https://doi.org/10.1016/j.ophtha.2010.01.058|
|Abstract:||Objective: To describe the natural history of branch retinal vein occlusion (BRVO) based on the best available evidence from the literature. Clinical Relevance: Branch retinal vein occlusion is the second most frequent major retinal vascular disease. Although several new treatments for BRVO are currently being introduced, data on its natural history are sparse. Methods: English language articles were retrieved using a keyword search of MEDLINE, EMBASE, Current Contents, and the Cochrane Library to November 13, 2008, supplemented by manually searching the references of review articles published within the last 5 years. All relevant observational studies evaluating the natural history of BRVO and all clinical trials evaluating BRVO interventions with an untreated control arm were independently identified by 2 investigators. Results: Of a total of 5965 citations retrieved, 24 eligible studies were identified and reviewed, providing 1608 eyes with BRVO with data on natural history. Visual acuity (VA) was moderately poor at baseline (<20/40). Although VA generally improved, with mean improvement ranging from 1 letter at 6 weeks to 28 letters up to 24 months, few studies reported improvement beyond 20/40. Over a 1-year period, 5% to 15% of eyes developed macular edema (ME), but of those with ME at baseline, 18% to 41% resolved. At baseline, 5% to 6% of eyes had bilateral BRVO, with 10% developing fellow eye involvement over time. There were few high-quality studies on other outcomes, including development of new vessels. Conclusions: Visual acuity generally improved in eyes with BRVO without intervention, although clinically significant improvement beyond 20/40 was uncommon. Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. © 2010 American Academy of Ophthalmology.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 26, 2018
WEB OF SCIENCETM
checked on Mar 26, 2018
checked on Mar 11, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.